macs monthly header with macs logo and graphic of medical professionals in training

The latest in substance use disorders and pain management education for healthcare providers

August 2023

Hello Anna,


Overdose Awareness Week, August 28 - September 3, is a time to honor those who have died from a drug overdose and those who go unseen. It's also a time to raise awareness, strengthen our efforts to prevent and reduce drug-related harm, and enhance substance use services. Get started by checking out these six simple steps providers can take to prevent overdose and save lives.


In Maryland, xylazine continues to show up in the illicit drug supply, but the Baltimore City harm reduction team is working to keep people who use drugs safe. As the need for increased access to overdose interventions grows, the FDA approved a new over the counter naloxone spray, RiVive, given its effectiveness in reversing the effects of overdose and availability without a prescription.


Buprenorphine remains a vital treatment for opioid use disorder, now made easier to prescribe with the removal of the x-waiver. However, some practitioners are still hesitant to prescribe this lifesaving medication. Fortunately, the MACS team of addiction medicine specialists are here to support Maryland prescribers with each step of the process. Register for the next MACS virtual training on buprenorphine for OUD to learn more and fulfill the training requirement for DEA license renewal or application.


Opioid use during pregnancy rose 131% between 2010 - 2017 followed by an 81% increase in drug overdose mortality among pregnant people from 2017 - 2020. To improve care and reduce stigma for pregnant people with substance use disorders, join our upcoming MACS for MOMs CME webinar.


-The MACS Team

Recovery Month is right around the corner! Click the link below to share a topic that you'd like to learn more about.

Submit a Recovery Month Topic

EDUCATION

Upcoming Opportunities

MACS Virtual Training

PCSS Half & Half Buprenorphine Training

Fulfills the 8-hour DEA training requirement upon completion of both the live & on demand training portions


Thursday, August 24 | 1:00 - 5:15 pm

Register
nurse examining pregnant patient

MACS for MOMs Webinar

Decreasing Stigma While Caring For Pregnant People with Substance Use


Thursday, August 31 | 12:00 - 1:00 pm

Register
dr. ramprashad presenting training

SAVE THE DATE: MACS Virtual Training

Opioid Use Disorder Treatment Integrated with Primary Care

Counts toward the 8-hour DEA training requirement


Thursday, September 28 | 12:00 - 2:00 pm

MACS ECHO Clinics

Save the dates for the 2023 ECHO Clinics fall cycle! In September, join our learning communities for continuous case-based discussions and didactic presentations linking expert specialist teams with healthcare providers and their practices. MACS ECHO Clinics count toward the required 8-hours of SUD training for DEA license renewal or registration.

Opioid Treatment Program ECHO



Wednesday, September 6

12:30 pm -1:30 pm

noun_pregnant woman_710364-teal.png

Maternal Health ECHO


Tuesday, September 12

8:00 am - 9:00 am

blue stethoscope with heart icon

Substance Use Disorder ECHO


Wednesday, October 18

12:30 - 1:30 pm

Learn more about MACS ECHO clinics

In Case You Missed It

MACS for MOMs Webinar

Motivational Interviewing for Pregnant Patients Living with Substance Use Disorder 

Watch

Conferences

mdapa 2023 with title and conference details in different shades of blue on white background

MdAPA CME Conference | MACS team members will be tabling

September 19 - 24 | Ocean City, MD

More info

NEWS

Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines


This study compared clinicians with traditional DATA 2000 waivers to those with education-exempted waivers and found challenges limiting buprenorphine prescribing, emphasizing the need to address these barriers for improved access.


Read more from JAMA...

ASAM Clinical Considerations: Buprenorphine Treatment of Opioid Use Disorder for Individuals Using High-potency Synthetic Opioids


Treatment of opioid use disorder with buprenorphine has evolved due to the ongoing OUD epidemic and increasing use of high-potency synthetic opioids. Based on expert consensus, this clinical consideration document addresses individualized strategies for buprenorphine initiation, withdrawal management, and dosing in the context of this novel drug supply. Annie Kleykamp, MACS Director of Research & Evaluation, co-authors the article.


Read more from Journal of Addiction Medicine...

Clinician views on reporting pregnant and birthing patients who use alcohol and/or drugs to child welfare


Read more from AJOG...

Primary Care at the Intersection of Lifestyle Interventions and Unhealthy Substance Use 



Read more and take the quiz for CE credit...

Drug Overdose Deaths Climbing Among US Adolescents



Read more and take the quiz for CE credit...

Holidays

MACS Phone Line Will Be Closed:

September 4 - Labor Day

August Observances

National Health Center Week

August 6 - 12

graphic of roadmap featuring route symbol

Overdose Awareness Week

August 28 - September 3

tan background with purple ribbon and overdose awareness day

National Fentanyl Prevention and Awareness Day

August 21

image of grains on table with fact about fentanyl

Follow us to stay connected:

Facebook  LinkedIn  Twitter  Instagram

RESOURCES

An Addiction Psychiatrist’s Encounter with a DEA Scammer

split image of close up of two people with their hands clasped together on a lap and two men talking outside

Provide Comments on the Harm Reduction Framework by 8/14

illustration showing crowd of diverse people dressed in wide range of colors.

Guide to Equity Terminology: Promoting Behavioral Health Equity through the Words We Use

Equitable Access to Mental Health and Substance Use Care: An Urgent Need

LinkedIn Share

Follow us:

Facebook  Twitter  LinkedIn  Instagram  YouTube